← Shelf·GHRH analog·IV.
Tesamorlin.
A synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), stabilized by a trans-3-hexenoyl modification at the N-terminus. Developed by Theratechnologies. FDA-reviewed 2010 for a single specific clinical indication (published in the FDA label).
GHRH is a hormone your hypothalamus makes to signal the pituitary. This is the stabilized synthetic analog researchers use when they need that signaling axis engaged in a study.
The one FDA-reviewed compound in the injectable-peptide category most researchers know by name. The regulatory dossier is unusually complete for a research peptide. The consumer-facing narrative online is usually about outcomes the label doesn't authorize us to discuss.
Straight talk
Straight talk: unlike most compounds on this shelf, tesamorelin has an FDA regulatory record — but for one specific clinical indication only. Every other use is off-label. The literature is real; the marketing pitches to a much broader audience than the label supports. Whether the research-grade compound in a given vial IS the same molecule as the FDA-approved drug of the same INN is exactly what a third-party COA is for. Buy on documentation, not on brand adjacency.
What the research studies
The literature, not a summary of it.
The core clinical record sits in the Theratechnologies-sponsored trials published in JAIDS, Clinical Infectious Diseases, and JCEM. Upstream GHRH pharmacology is Guillemin/Vale-lineage work. Read the research yourself:
Recommended vendor · Amino Club
≥ 99% by HPLC on the current lot — ILS Laboratories (ISO/IEC 17025). Vendor spells it 'Tesamorlin' (their spelling; the INN is 'tesamorelin').
$45.49 during Fall Sale (was $69.99)
35% off applied automatically at checkout when you land through this link.